News

The FDA granted orphan drug designation to LYT-200, a drug being investigated for treating acute myeloid leukemia.

The FDA has accepted the new drug application of ensartinib for the treatment of patients with metastatic ALK-positive non-small cell lung cancer.

Carlos Rojas, MD, discusses the mechanism of action of MK-1084, a selective KRAS G12C inhibitor.

It is a promising time for cellular therapy, and combinations with gene modification or other systemic or local therapies bode well for solid tumor development of this TIL therapy platform.

Introducing a checkpoint inhibitor like nivolumab for patients where chimeric antigen receptor T-cell therapy failed in multiple myeloma is a potential area of interest for researchers.

Matthew Matasar, MD, discusses the next steps for the development of ibrutinib given in combination with venetoclax for patients with mantle cell lymphoma, and potential challenges with using the combination.

Six CAR T-cell therapies have gained FDA approval across hematologic malignancy settings. These approvals have spurred further exploration for their use in solid tumors.

Pedro Barata, MD, MSc, discussed the importance of the NRG Oncology Semiannual Meeting and the forum it provides for oncologists to collaborate and optimize cancer treatment.

The BCR-ABL tyrosine kinase inhibitor TERN-701 has been granted an orphan drug designation from the FDA for the treatment of chronic myeloid leukemia.

Findings from the phase 3 ECHELON-3 trial demonstrated that brentuximab vedotin plus lenalidomide and rituximab led to improvements in overall survival among patients with diffuse large B-cell lymphoma.

Lori J. Wirth, MD, discussed advancements in diagnosing and treating thyroid cancer, offering community oncologists improved tools for identifying low-risk cancers, personalizing treatment, and exploring innovative approaches.

Musa Yilmaz, MD, discusses the most recent update of the phase 1/2 study of quizartinib, venetoclax, and decitabine in FLT3-internal tandem duplication mutated acute myeloid leukemia and the background behind this research.

Findings from a post hoc analysis of lurbinectedin for the treatment of small cell lung cancer showed that the agent was more effective and less toxic than topotecan.

Stephanie Lee, MD, discusses a study investigating belumosudil for chronic graft-vs-host disease.

Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.

Susan Bal, MD, discussed GPRC5D as an immunotherapeutic target in multiple myeloma and findings from a phase 1 study evaluating a novel CAR T-cell therapy working to target GPRC5D.

From bispecific antibodies transforming B-cell lymphoma treatment to immunotherapy breakthroughs in breast cancer and gene therapy innovations for hematologic malignancies, recent advancements offer hope.

Matthew Matasar, MD, discusses how ibrutinib given in combination with venetoclax compares with ibrutinib and placebo for the treatment of patients with relapsed/refractory mantle cell lymphoma.

Ariel Lopez-Chavez, MD, provided insights into the current landscape of small cell lung cancer treatment, highlighting approved options and ongoing research.

Identifying differences in pancreatic cancer subtypes could be at the center of developing targeted treatments in this challenging disease.

Jeremy Ramdial, MD, discussed a phase 1/2 study investigating the GemCloBu conditioning regimen for stem cell transplants in aggressive lymphomas.

Robert Dreicer, MD, MS, MACP, FASCO, discusses the limitations of using prostate-specific antigen levels alone to guide prostate cancer treatment.

Scott T. Tagawa, MD, MS, FACP, FASCO, highlights a key difference between oral androgen receptor inhibitor drugs and therapeutic radionuclides for the treatment of prostate cancer.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses that patients with advanced prostate cancer benefit from a multidisciplinary care team.

Adam D. Cohen, MD, discusses the new era of multiple myeloma treatment with bispecifics and CAR T-cell therapy.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed how mutations such as TP53, RB1, and PTEN impact overall survival in patients with metastatic prostate cancer.

Raajit K. Rampal, MD, PhD, discusses the established role of JAK inhibition for the treatment of myelofibrosis.

Jeff Auletta, MD, discusses findings from a study evaluationg posttransplant cyclophosphamide in unmatched stem cell transplants.

Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.

Samilia Obeng-Gyasi, MD, MPH, delved into the background and findings of this study assessing the correlation between neighborhood opportunity, allostatic load, and all-cause mortality among patients with breast cancer.